{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T22:07:35Z","timestamp":1784585255784,"version":"3.55.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,10,11]],"date-time":"2018-10-11T00:00:00Z","timestamp":1539216000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2018,10,11]],"date-time":"2018-10-11T00:00:00Z","timestamp":1539216000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["OPP1136158"],"award-info":[{"award-number":["OPP1136158"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s13063-018-2928-5","type":"journal-article","created":{"date-parts":[[2018,10,11]],"date-time":"2018-10-11T00:35:59Z","timestamp":1539218159000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Improved simplified clinical algorithm for identifying patients eligible for immediate initiation of antiretroviral therapy for HIV (SLATE II): protocol for a randomized evaluation"],"prefix":"10.1186","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6560-2964","authenticated-orcid":false,"given":"S","family":"Rosen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Maskew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A T","family":"Brennan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M P","family":"Fox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L","family":"Vezi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P D","family":"Ehrenkranz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W D F","family":"Venter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,10,11]]},"reference":[{"key":"2928_CR1","volume-title":"Guidelines For managing advanced HIV disease and rapid initiation of antiretroviral therapy","author":"World Health Organization","year":"2017","unstructured":"World Health Organization. Guidelines For managing advanced HIV disease and rapid initiation of antiretroviral therapy. Geneva: World Health Organization; 2017."},{"key":"2928_CR2","volume-title":"Same-day antiretroviral therapy (ART) initiation for HIV positive patients","author":"Y Pillay","year":"2017","unstructured":"Pillay Y. Same-day antiretroviral therapy (ART) initiation for HIV positive patients. Pretoria: National Department of Health; 2017."},{"key":"2928_CR3","volume-title":"Zambia consolidated guidelines for prevention and treatment of HIV infection 2018","author":"Zambia Ministry of Health","year":"2018","unstructured":"Zambia Ministry of Health. Zambia consolidated guidelines for prevention and treatment of HIV infection 2018. Lusaka: Ministry of Health; 2018."},{"key":"2928_CR4","volume-title":"Guidelines on use of antiretroviral drugs for treating and preventing HIV infection in Kenya 2016","author":"Ministry of Health National AIDS & STI Control Programme","year":"2016","unstructured":"Ministry of Health National AIDS & STI Control Programme. Guidelines on use of antiretroviral drugs for treating and preventing HIV infection in Kenya 2016. Nairobi: Ministry of Health; 2016."},{"key":"2928_CR5","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1007\/s10461-017-1877-4","volume":"22","author":"B Maughan-Brown","year":"2018","unstructured":"Maughan-Brown B, Kuo C, Galarraga O, Smith P, Lurie MN, Bekker L-G, et al. Stumbling blocks at the clinic: experiences of seeking HIV treatment and care in South Africa. AIDS Behav. 2018;22:765\u201373.","journal-title":"AIDS Behav"},{"key":"2928_CR6","doi-asserted-by":"publisher","first-page":"2543","DOI":"10.1007\/s10461-018-2101-x","volume":"22","author":"VA Earnshaw","year":"2018","unstructured":"Earnshaw VA, Bogart LM, Courtney I, Zanoni H, Bangsberg DR, Orrell C, et al. Exploring treatment needs and expectations for people living with HIV in South Africa: a qualitative study. AIDS Behav. 2018;22:2543\u201352.","journal-title":"AIDS Behav"},{"key":"2928_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/sextrans-2016-052970","volume":"93","author":"D Bukenya","year":"2017","unstructured":"Bukenya D, Wringe A, Moshabela M, Skovdal M, Ssekubugu R, Paparini S, et al. Where are we now? A multicountry qualitative study to explore access to pre-antiretroviral care services: a precursor to antiretroviral therapy initiation. Sex Transm Infect. 2017;93:1\u20135.","journal-title":"Sex Transm Infect"},{"key":"2928_CR8","doi-asserted-by":"publisher","first-page":"e1002015","DOI":"10.1371\/journal.pmed.1002015","volume":"13","author":"S Rosen","year":"2016","unstructured":"Rosen S, Maskew M, Fox MP, Nyoni C, Mongwenyana C, Malete G, et al. Initiating antiretroviral therapy for HIV at a patient\u2019s first clinic visit: the RapIT randomized controlled trial. PLoS Med. 2016;13:e1002015.","journal-title":"PLoS Med"},{"key":"2928_CR9","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1097\/QAD.0000000000001528","volume":"31","author":"LC Long","year":"2017","unstructured":"Long LC, Maskew M, Brennan AT, Mongwenyana C, Nyoni C, Malete G, et al. Initiating antiretroviral therapy for HIV at a patient\u2019s first clinic visit: a cost-effectiveness analysis of the rapid initiation of treatment randomized controlled trial. AIDS. 2017;31:1611\u20139.","journal-title":"AIDS"},{"key":"2928_CR10","doi-asserted-by":"publisher","first-page":"e016340","DOI":"10.1136\/bmjopen-2017-016340","volume":"7","author":"S Rosen","year":"2017","unstructured":"Rosen S, Fox MP, Larson BA, Brennan AT, Maskew M, Tsikhutsu I, et al. Simplified clinical algorithm for identifying patients eligible for immediate initiation of antiretroviral therapy for HIV (SLATE): protocol for a randomised evaluation. BMJ Open. 2017;7:e016340.","journal-title":"BMJ Open"},{"key":"2928_CR11","volume-title":"Guidelines for intensified tuberculosis case-finding and isoniazid preventive therapy for people living with HIV in resource-constrained settings","author":"World Health Organization","year":"2011","unstructured":"World Health Organization. Guidelines for intensified tuberculosis case-finding and isoniazid preventive therapy for people living with HIV in resource-constrained settings. Geneva: World Health Organization; 2011."},{"key":"2928_CR12","doi-asserted-by":"publisher","first-page":"e1002106","DOI":"10.1371\/journal.pmed.1002106","volume":"13","author":"S Rosen","year":"2016","unstructured":"Rosen S, Fox MP, Larson B, Sow PS, Ehrenkranz PD, Venter F, et al. Accelerating the uptake and timing of antiretroviral therapy initiation in sub-Saharan Africa: an operations research agenda. PLoS Med. 2016;13:e1002106.","journal-title":"PLoS Med"},{"key":"2928_CR13","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.jctube.2016.03.002","volume":"3","author":"M Lanzafame","year":"2016","unstructured":"Lanzafame M, Vento S. Tuberculosis-immune reconstitution inflammatory syndrome. J Clin Tuberc Other Mycobact Dis. 2016;3:6\u20139.","journal-title":"J Clin Tuberc Other Mycobact Dis"},{"key":"2928_CR14","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/S1473-3099(08)70184-1","volume":"8","author":"G Meintjes","year":"2008","unstructured":"Meintjes G, Lawn SD, Scano F, Maartens G, French MA, Worodria W, et al. Tuberculosis-associated immune reconstitution inflammatory syndrome: case definitions for use in resource-limited settings. Lancet Infect Dis. 2008;8:516\u201323.","journal-title":"Lancet Infect Dis"},{"key":"2928_CR15","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/S1473-3099(10)70026-8","volume":"10","author":"M M\u00fcller","year":"2010","unstructured":"M\u00fcller M, Wandel S, Colebunders R, Attia S, Furrer H, Egger M, et al. Immune reconstitution inflammatory syndrome in patients starting antiretroviral therapy for HIV infection: a systematic review and meta-analysis. Lancet Infect Dis. 2010;10:251\u201361.","journal-title":"Lancet Infect Dis"},{"key":"2928_CR16","volume-title":"Feasibility of using determine-TB LAM test in HIV-infected adults in programmatic conditions","author":"S Mathabire","year":"2017","unstructured":"Mathabire S, Cossa L, Mpunga J, Manhica I, Amoros Quiles I, Molfino L. Feasibility of using determine-TB LAM test in HIV-infected adults in programmatic conditions. Geneva: International Aids Society; 2017."},{"key":"2928_CR17","first-page":"27","volume":"27","author":"T Smart","year":"2012","unstructured":"Smart T. Determine LAM urine antigen TB test is highly cost\u00adeffective for use in hospitalised people living with HIV. London. AIDSMap. 2012;27:27.","journal-title":"AIDSMap"},{"key":"2928_CR18","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1097\/QAD.0b013e3283553685","volume":"26","author":"SD Lawn","year":"2012","unstructured":"Lawn SD, Kerkhoff AD, Vogt M, Wood R. Clinical significance of lipoarabinomannan (LAM) detection in urine using a low-cost point-of-care diagnostic assay for HIV-associated tuberculosis. AIDS. 2012;26:1635\u201343.","journal-title":"AIDS"},{"key":"2928_CR19","doi-asserted-by":"publisher","first-page":"e0170976","DOI":"10.1371\/journal.pone.0170976","volume":"12","author":"H Huerga","year":"2017","unstructured":"Huerga H, Ferlazzo G, Bevilacqua P, Kirubi B, Ardizzoni E, Wanjala S, et al. Incremental yield of including Determine-TB LAM assay in diagnostic algorithms for hospitalized and ambulatory HIV-positive patients in Kenya. PLoS One. 2017;12:e0170976.","journal-title":"PLoS One"},{"key":"2928_CR20","first-page":"26","volume-title":"TB diagnosis in HIV+ patients in Mozambique. A field study of combined point-of-care evaluation with GeneXpert, LAM and symptom screening","author":"F Ciccacci","year":"2017","unstructured":"Ciccacci F, et al. TB diagnosis in HIV+ patients in Mozambique. A field study of combined point-of-care evaluation with GeneXpert, LAM and symptom screening. Paris: Abstract TUPEB0370), IAS 2017; 2017. p. 26\u20139."},{"key":"2928_CR21","volume-title":"The use of lateral flow urine lipoarabinomannan assay (LF-LAM) for the diagnosis and screening of active tuberculosis in people living with HIV TB","author":"World Health Organization","year":"2015","unstructured":"World Health Organization. The use of lateral flow urine lipoarabinomannan assay (LF-LAM) for the diagnosis and screening of active tuberculosis in people living with HIV TB. Geneva: World Health Organization; 2015."},{"key":"2928_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/srep19992","volume":"6","author":"PK Drain","year":"2016","unstructured":"Drain PK, Gounder L, Sahid F, Moosa MYS. Rapid urine LAM testing improves diagnosis of expectorated smear-negative pulmonary tuberculosis in an HIV-endemic region. Sci Rep. 2016;6:1\u20139.","journal-title":"Sci Rep"},{"key":"2928_CR23","unstructured":"Health-e. Quicker TB test available for HIV patients in SA. Health-e News. July 27, 2017; \n                    https:\/\/www.health-e.org.za\/2017\/07\/27\/quicker-tb-test-available-hiv-patients-sa\/\n                    \n                  ."},{"key":"2928_CR24","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1097\/QAD.0b013e32834564e9","volume":"25","author":"EJ Mills","year":"2011","unstructured":"Mills EJ, Bakanda C, Birungi J, Mwesigwa R, Chan K, Ford N, et al. Mortality by baseline CD4 cell count among HIV patients initiating antiretroviral therapy: evidence from a large cohort in Uganda. AIDS. 2011;25:851\u20135.","journal-title":"AIDS"},{"issue":"1","key":"2928_CR25","doi-asserted-by":"publisher","first-page":"e17","DOI":"10.1097\/QAI.0b013e31829ceb14","volume":"65","author":"RJ Lessells","year":"2014","unstructured":"Lessells RJ, Mutevedzi PC, Iwuji CC, Newell M-L. Reduction in early mortality on antiretroviral therapy for adults in rural South Africa since change in CD4+ cell count eligibility criteria. J Acquir Immune Defic Syndr. 2014;65(1):e17\u201324.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2928_CR26","doi-asserted-by":"publisher","first-page":"18908","DOI":"10.7448\/IAS.17.1.18908","volume":"17","author":"M Osler","year":"2014","unstructured":"Osler M, Hilderbrand K, Hennessey C, Arendse J, Goemaere E, Ford N, et al. A three-tier framework for monitoring antiretroviral therapy in high HIV burden settings. J Int AIDS Soc. 2014;17:18908.","journal-title":"J Int AIDS Soc"},{"key":"2928_CR27","volume-title":"National adherence guidelines for chronic diseases (HIV, TB and NCDs), 7 April 2015","author":"South African National Department of Health","year":"2015","unstructured":"South African National Department of Health. National adherence guidelines for chronic diseases (HIV, TB and NCDs), 7 April 2015. Pretoria: National Department of Health; 2015."},{"key":"2928_CR28","series-title":"24th Conference on Retroviruses and Opportunistic Infections (CROI 2018), Boston","volume-title":"Effect of fast track initiation counselling on ART initiation in South Africa","author":"S Pascoe","year":"2018","unstructured":"Pascoe S, Fox MP, Huber A, Murphy J, Phokojoe M, Gorgens M, et al. Effect of fast track initiation counselling on ART initiation in South Africa. 24th Conference on Retroviruses and Opportunistic Infections (CROI 2018), Boston, 2018."},{"key":"2928_CR29","volume-title":"Donor government funding for HIV in low- and middle-income countries in 2016","author":"Kaiser Family Foundation","year":"2017","unstructured":"Kaiser Family Foundation. Donor government funding for HIV in low- and middle-income countries in 2016. San Francisco: Kaiser Family Foundation; 2017."},{"key":"2928_CR30","volume-title":"Ending AIDS: Progress towards the 90\u201390\u201390 targets. Global AIDS Update 2017","author":"UNAIDS","year":"2017","unstructured":"UNAIDS. Ending AIDS: Progress towards the 90\u201390\u201390 targets. Global AIDS Update 2017. Geneva: UNAIDS; 2017."},{"key":"2928_CR31","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/1758-2652-14-48","volume":"14","author":"BM Wajanga","year":"2011","unstructured":"Wajanga BM, Kalluvya S, Downs JA, Johnson WD, Fitzgerald DW, Peck RN. Universal screening of Tanzanian HIV-infected adult inpatients with the serum cryptococcal antigen to improve diagnosis and reduce mortality: an operational study. J Int AIDS Soc. 2011;14:48.","journal-title":"J Int AIDS Soc"},{"key":"2928_CR32","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/j.medmal.2012.05.012","volume":"42","author":"EF Aoussi","year":"2012","unstructured":"Aoussi EF, Ehui E, Demb JP, Kolia-Diafouka P, Elloh NF, Ouattara SI, et al. Cryptoccocal meningitis and HIV in the era of HAART in Cote d\u2019Ivoire. Med Mal Infect. 2012;42:349\u201354.","journal-title":"Med Mal Infect"},{"key":"2928_CR33","doi-asserted-by":"publisher","first-page":"e1001055","DOI":"10.1371\/journal.pmed.1001055","volume":"8","author":"L Long","year":"2011","unstructured":"Long L, Brennan A, Fox MP, Ndibongo B, Jaffray IA, Sanne I, et al. Treatment outcomes and cost-effectiveness of shifting management of stable ART patients to nurses in South Africa: an observational cohort. PLoS Med. 2011;8:e1001055.","journal-title":"PLoS Med"}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-018-2928-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13063-018-2928-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-018-2928-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,15]],"date-time":"2020-05-15T11:27:09Z","timestamp":1589542029000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-018-2928-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,11]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["2928"],"URL":"https:\/\/doi.org\/10.1186\/s13063-018-2928-5","relation":{},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,11]]},"assertion":[{"value":"7 June 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 September 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 October 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The SLATE II study protocol has been approved by the Boston University Institutional Review Board (H-37010) and the University of the Witwatersrand Human Research Ethics Committee (Medical) (171011). Written informed consent was obtained from all study subjects prior to enrollment.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"PDE is an employee of the Bill & Melinda Gates Foundation, which is funding this work. WDFV sits on antiretroviral initiation guideline committees, both South African and international. WDFV has accepted speaking honoraria from multiple manufacturers of antiretrovirals and is on several of their advisory boards. The remaining authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"548"}}